HRMY Harmony Biosciences Holdings, Inc.

CIK 0001802665 30 ready 8-Ks latest May 14, 2026, 4:31 PM ET RSS · JSON

Activity: NORMAL 1 filings / 30d vs 1 baseline

Ready 8-Ks 30

Latest filing May 14, 2026, 4:31 PM ET

Top materiality 0.85

Event mix earnings ×14 · other_material ×6 · leadership ×6

Sentiment 18 pos · 3 neg · 9 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for HRMY

Highest-materiality recent filing

Harmony Biosciences Q4 revenue $243.8M (+21% YoY); guides WAKIX to $1B+ in 2026

February 24, 2026, 6:59 PM ET earnings materiality 0.85 positive item 2.02 item 7.01 item 9.01

Full-year 2025 WAKIX revenue $868.5M, up 22% YoY; Q4 GAAP EPS $0.38, adjusted EPS $0.57.
2026 net revenue guidance for WAKIX: $1.0-1.04B, targeting blockbuster status.

Read filing →

May 14, 2026, 4:31 PM ET other material materiality 0.15 neutral item 5.07

Harmony Biosciences shareholders elect four directors, ratify auditor, approve say-on-pay at 2026 annual meeting

All four Class III director nominees elected: Geno Germano (44.96M for), Troy Ignelzi (32.81M), Ron Philip (31.83M), Andreas Wicki (25.11M).
May 7, 2026, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Harmony Biosciences Q1 revenue $215.4M (+17% YoY); reaffirms FY2026 guidance >$1B

Q1 net product revenue $215.4M, up 17% YoY; diluted EPS $0.55 vs $0.78 in Q1 2025.
April 14, 2026, 7:59 PM ET leadership materiality 0.60 neutral item 5.02 item 7.01 item 9.01

Harmony Biosciences appoints Glenn Reicin as CFO; reaffirms 2026 revenue guidance of $1.0-$1.04B

Sandip Kapadia steps down as CFO effective April 14, 2026 to pursue other career opportunities.
April 2, 2026, 7:59 PM ET leadership materiality 0.50 neutral item 5.02 item 7.01 item 9.01

Harmony Biosciences appoints Peter Anastasiou as COO; adds Troy Ignelzi to Board

Peter Anastasiou named SEVP and COO, effective April 2, 2026; resigns from Board.
February 24, 2026, 6:59 PM ET earnings materiality 0.85 positive item 2.02 item 7.01 item 9.01

Harmony Biosciences Q4 revenue $243.8M (+21% YoY); guides WAKIX to $1B+ in 2026

Full-year 2025 WAKIX revenue $868.5M, up 22% YoY; Q4 GAAP EPS $0.38, adjusted EPS $0.57.
January 12, 2026, 6:59 PM ET earnings materiality 0.80 positive item 2.02 item 7.01 item 9.01

Harmony Biosciences reports ~$868M FY2025 WAKIX revenue; guides $1.0-1.04B in 2026

Preliminary Q4 2025 WAKIX net revenue ~$243M; FY2025 ~$868M, up ~21% YoY.
November 4, 2025, 6:59 PM ET earnings materiality 0.85 positive item 2.02 item 7.01 item 9.01

Harmony Biosciences Q3 revenue $239.5M (+29% YoY); raises FY2025 guidance to $845-865M

Q3 net revenue $239.5M (WAKIX), +29% YoY; GAAP EPS $0.87, adjusted EPS $1.08.
October 23, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

Harmony Biosciences raises 2025 revenue guidance after Q3 WAKIX revenue of $239M (+29% YoY)

Preliminary Q3 2025 WAKIX net revenue of ~$239M, up 29% year-over-year.
September 24, 2025, 7:59 PM ET other material materiality 0.75 negative item 7.01 item 9.01

Harmony Biosciences' Phase 3 ZYN002 trial in Fragile X syndrome fails primary endpoint

RECONNECT study did not meet primary endpoint of improvement in social avoidance; higher than expected placebo response cited.
August 5, 2025, 7:59 PM ET earnings materiality 0.85 positive item 2.02 item 7.01 item 9.01

Harmony Biosciences Q2 revenue $200.5M (+16% YoY); EPS $0.68; reaffirms FY guidance $820-860M

Net product revenue $200.5M (+16% YoY); GAAP net income $39.8M ($0.68 diluted EPS); non-GAAP adj. net income $53.8M ($0.92 diluted EPS).
June 11, 2025, 7:59 PM ET other material materiality 0.50 positive item 7.01 item 9.01

Harmony Biosciences Presents Preclinical Data for BP1.15205 OX2R Agonist in Narcolepsy

Data presented at SLEEP 2025 showed significant wake-promoting and cataplexy-suppressing effects in transgenic mouse model of narcolepsy type 1.
June 5, 2025, 7:59 PM ET litigation materiality 0.75 positive item 8.01 item 9.01

Harmony settles Lupin ANDA litigation; generic WAKIX entry delayed to 2030

Lupin receives license to launch generic WAKIX no earlier than January 2030 (July 2030 with pediatric exclusivity).
May 15, 2025, 7:59 PM ET other materiality 0.00 neutral item 5.07

Harmony Biosciences shareholders re-elect three Class II directors and ratify auditor

Elected Class II directors: Juan Sabater (25.9M for, 18.0M withheld), Gary Sender (35.0M for, 8.9M withheld), Linda Szyper (34.9M for, 9.0M withheld).
May 6, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

Harmony Biosciences reports 20% Q1 revenue growth; reaffirms 2025 guidance $820-860M

Q1 net revenue $184.7M, +20% YoY; GAAP net income $45.6M ($0.78 diluted EPS).
April 3, 2025, 7:59 PM ET leadership materiality 0.35 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change

Harmony Biosciences appoints Ron Philip to Board of Directors effective April 2, 2025

Ron Philip, age 51, appointed as Class III director filling vacancy from Jack Bech Nielsen's resignation.
March 24, 2025, 7:59 PM ET leadership materiality 0.65 positive item 5.02 item 8.01 item 9.01 ◈ executive_change

Harmony Biosciences names Takeda veteran Adam Zaeske as CCO; Dierks steps down

Jeffrey Dierks steps down as CCO effective March 31, 2025; receives $476,215 cash and accelerated vesting for 2025 awards.
February 25, 2025, 6:59 PM ET earnings materiality 0.85 positive item 2.02 item 7.01 item 9.01

Harmony Biosciences Q4 2024 net revenue $201.3M, FY $714.7M; guides 2025 $820-860M

Q4 2024 net product revenue $201.3M (+20% YoY); FY 2024 net revenue $714.7M (+23% YoY).
January 13, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

Harmony Biosciences: Q4 WAKIX revenue ~$201M, FY2024 ~$714M; guides 2025 $820-860M

Preliminary Q4 2024 net product revenue ~$201M (vs $168.4M Q4 2023); FY2024 ~$714M (vs $582M, +23% YoY).
November 1, 2024, 7:59 PM ET other material materiality 0.65 negative item 8.01 item 9.01

Secondary offering of 8M shares by certain shareholders; company receives no proceeds

Selling Shareholders sold 8,000,000 shares of common stock in a registered public offering.
October 29, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 7.01 item 9.01

Harmony Biosciences Q3 net revenue $186M (+16% YoY); reiterates FY2024 guidance $700-720M

GAAP net income $46.1M ($0.79 diluted EPS) vs $38.5M ($0.63) in Q3 2023; non-GAAP adjusted EPS $1.03.
October 1, 2024, 7:59 PM ET other material materiality 0.85 positive item 7.01 item 9.01

Harmony Biosciences highlights best-in-class orexin-2 agonist, $3B revenue goal at Investor Day

BP1.15205 orexin-2 agonist shows highest potency vs. all publicly disclosed competitors, potential best-in-class.
August 6, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

Harmony Q2 net revenue $172.8M (+29% YoY); non-GAAP EPS $1.05 vs $0.76; FY guidance reaffirmed

Net product revenue $172.8M for Q2 2024, up 29% from $134.2M in Q2 2023.
July 1, 2024, 7:59 PM ET leadership materiality 0.10 neutral item 5.02 item 8.01 item 9.01 ◈ executive_change

Board member Jack Bech Nielsen resigns for health reasons; subsidiary Zynerba renamed

Jack Bech Nielsen resigned from the Board effective June 27, 2024 due to health reasons; no disagreements with the company.
May 29, 2024, 7:59 PM ET other material materiality 0.10 neutral item 5.07

Harmony Biosciences shareholders elect all three Class I directors and ratify Deloitte as auditor

Jeffrey S. Aronin, R. Mark Graf, and Jeffrey M. Dayno elected as Class I directors with votes ranging from 18.3M to 20.6M for.
May 3, 2024, 7:59 PM ET leadership materiality 0.45 neutral item 5.02 item 9.01 ◈ executive_change

Kumar Budur promoted to EVP and Chief Medical & Scientific Officer at Harmony Biosciences

Appointed EVP & Chief Medical & Scientific Officer effective May 1, 2024.
April 30, 2024, 7:59 PM ET earnings materiality 0.85 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Harmony Biosciences Q1 revenue $154.6M (+30% YoY); reaffirms FY2024 guidance $700-720M

Q1 net revenue $154.6M (+30% YoY); GAAP EPS $0.67, adjusted EPS $0.88.
April 11, 2024, 7:59 PM ET M&A materiality 0.75 positive item 1.01 item 8.01 item 9.01

Harmony Biosciences obtains exclusive license for orexin-2 receptor agonist from Bioprojet

Upfront fee $25.5M; development/regulatory milestones up to $127.5M, sales milestones up to $240M.
February 22, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Harmony Biosciences Q4 2023 revenue $168.4M, guides 2024 revenue $700-720M

WAKIX net revenue $168.4M in Q4 2023 (+31% YoY); full year $582.0M (+33%).
January 8, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases ×3

Harmony Biosciences reports Q4 net product revenue ~$168M, FY2023 ~$582M; 2024 guidance $700-720M

Preliminary Q4 net product revenue ~$168M, up ~31% YoY; FY2023 ~$582M, up ~33% YoY.
December 7, 2023, 6:59 PM ET M&A materiality 0.60 negative item 9.01

Harmony files Zynerba FY2022 audited financials; net loss $35M, accumulated deficit $274.5M

Zynerba FY2022 net loss $35.0M ($0.82 loss per share); no revenue; R&D expense $21.1M, G&A $14.2M.

Executive changes

Appointed

Ron Philip

Class III director

HRMY · Harmony Biosciences Holdings, Inc.

Effective: 2025-04-02
Filed: April 3, 2025, 7:59 PM ET

Effective April 2, 2025, the Board of Directors (the “Board”) of Harmony Biosciences Holdings, Inc. (the “Company”) appointed Ron Philip, age 51, as a Class III director, filling the previously announced vacancy in the Board created by the resignation of Jack Bech Nielsen effective June 27, 2024.

Departed

Jeffrey Dierks

Chief Commercial Officer

HRMY · Harmony Biosciences Holdings, Inc.

Effective: 2025-03-31
Filed: March 24, 2025, 7:59 PM ET

Jeffrey Dierks will be departing from the Company as its Chief Commercial Officer, effective as of March 31, 2025 (the “Effective Date”), for personal reasons.

Departed

Jack Bech Nielsen

Director

HRMY · Harmony Biosciences Holdings, Inc.

Effective: 2024-06-27
Filed: July 1, 2024, 7:59 PM ET

On June 27, 2024, Jack Bech Nielsen notified the Board of Directors (the “Board”) of Harmony Biosciences Holdings, Inc. (the “Company”) that he is resigning from the Board effective immediately, due to health reasons.

Role change

Kumar Budur

Executive Vice President and Chief Medical & Scientific Officer

HRMY · Harmony Biosciences Holdings, Inc.

Effective: 2024-05-01
Filed: May 3, 2024, 7:59 PM ET

appointed Kumar Budur, M.D., M.S., the Company’s Chief Medical Officer, to the title of Executive Vice President and Chief Medical & Scientific Officer (the “Appointment”), effective on May 1, 2024

Earnings & guidance

2026-Q1 EPS reported $0.55 filing →

Materiality & sentiment trend

Max materiality 0.85 · Median 0.75 · Most common event earnings

18 positive 3 negative 9 neutral

source · HRMY on sec.gov